Key result
New Cochrane protocol will evaluate switching 5-ASA therapies for maintaining remission in ulcerative colitis.
Why the study?
To assess the probability of failure to maintain clinical remission, endoscopic remission, or both, as well as safety, when switching from SASP or oral 5-ASA to another oral 5-ASA drug in adult ulcerative colitis patients.
Systematic Review
Answers are grounded in this paper and cite their sources.
Protocol for 5-ASA switch evaluation in UC; leaves open whether switch maintains remission at 52 weeks.
OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the probability of failure to maintain clinical remission, endoscopic remission, or both, following a switch from SASP or oral 5-ASA drug (comparator) to another oral 5-ASA drug (experimental) in adult ulcerative colitis patients at 52 weeks of follow-up. The intervention of switching to the experimental drug will be compared to the continuation of the comparator drug. To assess the safety of switching from SASP or oral 5-ASA to another oral 5-ASA drug in the aforementioned population.
No takes yet. Share an insight, caveat, or question.
Abed et al. (2026) conducted a systematic review in Ulcerative colitis. Another oral 5-ASA drug vs. Continuation of SASP or oral 5-ASA drug was evaluated on Failure to maintain clinical remission, endoscopic remission, or both. This is a protocol for a Cochrane Review to assess switching from sulphasalazine or oral 5-ASA to another oral 5-ASA drug in adult ulcerative colitis patients; no results are available yet.
Synapse has enriched 10 related papers. Consider them for comparative context: